KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+3.57%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$288M
AUM Growth
+$288M
(-9.6%)
Cap. Flow
-$37.7M
Cap. Flow
% of AUM
-13.07%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
–
Increased
3
Reduced
7
Closed
3
Top Buys
| 1 |
Exelixis
EXEL
|
$10.2M |
| 2 |
Alkermes
ALKS
|
$23.2K |
| 3 |
NextCure
NXTC
|
$599 |
Top Sells
| 1 |
Enanta Pharmaceuticals
ENTA
|
$27.9M |
| 2 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
$6.9M |
| 3 |
IVC
Invacare Corporation
IVC
|
$4.24M |
| 4 |
Travere Therapeutics
TVTX
|
$3.33M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$2.57M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $44.3M | 15.35% | 204,812 -2,475 | -1% | -$535K |
|
|
2
Regeneron Pharmaceuticals
REGN
$61.5B
| $43.6M | 15.13% | 69,080 -4,063 | -6% | -$2.57M |
|
|
3
Enanta Pharmaceuticals
ENTA
$180M
| $42.2M | 14.63% | 564,102 -372,675 | -40% | -$27.9M |
|
4
McKesson
MCK
$85.4B
| $38.9M | 13.49% | 156,424 -8,167 | -5% | -$2.03M |
|
|
5
Alkermes
ALKS
$4.78B
| $33.6M | 11.64% | 1,442,965 +998 | +0.1% | +$23.2K |
|
|
6
Exelixis
EXEL
$10.1B
| $28.5M | 9.87% | 1,557,119 +557,119 | +56% | +$10.2M |
|
|
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $27M | 9.37% | 538,967 -6,616 | -1% | -$332K |
|
8
Biogen
BIIB
$19.4B
| $24.7M | 8.58% | 103,053 -149 | -0.1% | -$35.7K |
|
|
EGRX
9
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $5.42M | 1.88% | 106,487 -1,286 | -1% | -$65.5K |
|
|
10
NextCure
NXTC
$13.5M
| $186K | 0.06% | 31,027 +100 | +0.3% | +$599 |
|
|
11
Travere Therapeutics
TVTX
$1.56B
| – | – | -137,203 | Closed | -$3.33M |
|
|
IVC
12
DELISTED
Invacare Corporation
IVC
| – | – | -891,259 | Closed | -$4.24M |
|
|
SRGA
13
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| – | – | -6,332,945 | Closed | -$6.9M |
|